Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
New Treatment Slows Down Progression of AMD, RP
A breakthrough study has unveiled a promising advancement in the treatment of incurable eye diseases such as age-related macular degeneration and retinitis pigmentosa. Researchers have successfully integrated anti-inflammatory drugs into a hydrogel, aiming to combat inflammation in the retina while…
Ocular Therapeutix Reports Promising Axpaxli Results in DR Study
Ocular Therapeutix announced positive topline results from its phase 1 HELIOS study, which evaluated the safety, tolerability, and efficacy of Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema…
Caplin Granted USFDA Approval for Key Ophthalmic Solution
Caplin Steriles Limited (Caplin), a subsidiary of Caplin Point Laboratories Limited, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Ophthalmic Solution 0.5%. This product is…
Medevise Consulting Receives ISO13485 Certification
Medevise Consulting, a strategic consultancy specializing in the ophthalmic sector, announced that it has received ISO13485 certification. This certification marks a significant achievement on the company’s third anniversary, underscoring its commitment to quality and operational excellence alongside its adeptness in…
Kiora Receives Key Grant for Clinical Trials in Vision Impairment
Kiora Pharmaceuticals announced that it has secured a grant from the Choroideremia Research Foundation (CRF) to support novel clinical trial endpoints for inherited retinal diseases (IRDs). The grant will fund the validation of the Multiluminence Orientation & Mobility (MLOM™) suite…
DOJ Files Lawsuit Against Regeneron Over Eylea Pricing
The U.S. Department of Justice (DOJ) has initiated a lawsuit against Regeneron Pharmaceuticals under the False Claims Act (FCA), accusing the biotechnology company of fraudulently inflating Medicare reimbursement rates. According to the DOJ, Regeneron submitted false average sales price reports…
Lenz Therapeutics Reports Study Success for Presbyopia
Lenz Therapeutics announced positive topline results from its Phase 3 CLARITY study, evaluating two investigational formulations, LNZ100 and LNZ101, aimed at treating presbyopia. The study’s findings showcase the effectiveness and safety of these formulations, particularly highlighting LNZ100 (1.75% aceclidine) for…
Zeiss Completes Acquisition of DORC
In a significant move for the ophthalmology sector, Carl Zeiss Meditec announced the successful acquisition of 100% shares of the Dutch Ophthalmic Research Center (DORC), a transaction that has now received all necessary regulatory approvals. This acquisition from Eurazeo SE,…
Qlaris Bio Begins Phase 2 Trials of QLS-111 for Eye Conditions
Qlaris Bio has commenced two critical Phase 2 trials in the United States for its innovative intraocular pressure (IOP)-lowering product, QLS‑111. These masked, randomized clinical trials are designed to investigate the efficacy of QLS‑111 in patients suffering from ocular hypertension…
West Point and Verséa Sign Supply Deal for Ocular Products
In a significant move for ocular health and treatment, West Point Optical Group (WPOG), the operator of 86 Pearle Vision stores, has joined forces with Verséa Ophthalmics in an exclusive partnership supply agreement. Under this new deal, Verséa Ophthalmics is…